Oncology Meeting jointly organised by PERABOI and Gene Solutions (Feb 29, 2024)

Preceding the 2024 Asia Pacific Breast Cancer Summit (APBCS) in Bali this year, Gene Solutions and PERABOI jointly host Regional Oncology Expert Meeting: The Application of Personalized Cancer Monitoring and Tracking to unravel Unmet Needs in Breast Cancer Management.

The meeting will be held at Melia Bali Hotel, Nusa Dua, Bali Indonesia on Thursday, February 29, from 16:30 to 19:30 WITA (GMT+8).

In the era of precision medicine and individualized treatment, molecular profiling of cancer can guide treatment decision, monitor response, and predict clinical outcome. Emerging evidence has suggested that circulating tumor DNA change correlates with treatment response and predates radiological relapse. The objectives of the meeting include:

  • Discuss experiences and unmet need in cancer management
  • To showcase innovative solutions on detecting MRD in solid tumor
  • To exchange views and identify key challenges with regard to implementation of minimal residual disease (MRD) in a clinical setting
The application of personalized cancer monitoring and tracking to unravel unmet needs in breast cancer management
The application of personalized cancer monitoring and tracking to unravel unmet needs in breast cancer management

This meeting is part of a series of Regional Expert Meetings that Gene Solutions will be organising across Asia to facilitate collaboration among clinical centres driving genomic applications that make an impact to patient outcomes.

Direct any questions regarding this event to Dr. Hera Noviana, Oncology Scientific Manager, [email protected]

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More